Top

Published in:

Open Access 01-12-2008 | Review

Novel therapies in genitourinary cancer: an update

Authors: David Chu, Shenhong Wu

Published in: Journal of Hematology & Oncology | Issue 1/2008

Abstract

In recent years, new treatment for renal cell carcinoma (RCC) has been a spotlight in the field of cancer therapeutics. With several emerging agents branded as 'targeted therapy' now available, both medical oncologists and urologists are progressively more hopeful for better outcomes. The new remedies may provide patients with improved survival and at the same time less toxicity when compared to traditional cytotoxic agents. This article will center on current and emerging treatment strategies for advanced RCC and other GU malignancies with updates from 2008 annual ASCO meeting.

Results Surveillance Epidemiology and End: National Cancer Institute. 2008, [http://www.seer.cancer.gov]

Patel P, Chaganti R, Motzer R: Targeted therapy for metastatic renal cell carcinoma. Br J Cancer. 2006, 94: 614-PubMedCentralPubMed

Pantuck A, Zisman A, Belldegrun A: The changing natural history of renal cell carcinoma. Journal of Urology. 2001, 166: 1611-10.1016/S0022-5347(05)65640-6.CrossRefPubMed

Cohen H, McGovern F: Medical progress: renal-cell carcinoma. New England Journal of Medicine. 2005, 353: 2477-90. 10.1056/NEJMra043172.CrossRefPubMed

Snow R, Schellhammer P: Spontaneous regression of metastatic renal cell carcinoma. Urology. 1982, 20: 177-181. 10.1016/0090-4295(82)90356-9.CrossRefPubMed

Motzer R, Bander N, Nanus D: Renal-cell carcinoma. New England Journal of Medicine. 1996, 335: 865-875. 10.1056/NEJM199609193351207.CrossRefPubMed

Negrier S, Escudier B, Lasset C: Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. New England Journal of Medicine. 1998, 338: 1272-10.1056/NEJM199804303381805.CrossRefPubMed

Linehan WM, Walther MM, Zbar B: The genetic basis of cancer of the kidney. J Urol. 2003, 170: 2163-72. 10.1097/01.ju.0000096060.92397.ed.CrossRefPubMed

Linehan WM, Vasselli J, Srinivasan R: Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin Cancer Res. 2004, 10: 6282S-9S. 10.1158/1078-0432.CCR-050013.CrossRefPubMed

10.

Wilhelm SC: D: BAY 43-9006: preclinical Data. Current Pharmac Des. 2002, 8: 2255-10.2174/1381612023393026.CrossRef

11.

Ratain MET, Stadler W: Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 2006, 24: 2505-10.1200/JCO.2005.03.6723.CrossRefPubMed

12.

Escudier B, Eisen T, Stadler W: Sorafenib in advanced clear-cell renal-cell carcinoma. New England Journal of Medicine. 2007, 356: 125-10.1056/NEJMoa060655.CrossRefPubMed

13.

Bukowski R, Eisen T, Szczylik C: Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis. (Abstract). Journal of Clinical Oncology. 2007, 25: 240s-10.1200/JCO.2007.11.5154.CrossRef

14.

Szczylik C, Demkow T, Staehler M, Rolland F: Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results. Journal of Clinical Oncology 2007 ASCO annual meeting. Chicago, Illinois. 2007, 240s-

15.

Shepard D, Rini B, Garcia J, Hutson P: A multicenter prospective trial of sorafenib in patients with metastatic clear cell renal cell carcinoma refractory to prior sunitinib or bevacizumab. Journal of Clinical Oncology 2008 ASCO annual meeting Chicago, Illinois. 2008, 280s-

16.

Chu D, Lacouture ME, Fillos T, Wu S: Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol. 2008, 47: 176-86. 10.1080/02841860701765675.CrossRefPubMed

17.

Mendel D, Laird A, Xin X: In vivo antitumor activity of SU 11248 a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clinical Cancer Research. 2003, 9: 327-337.PubMed

18.

Gordon M, Mendelson D, Guirguis R: ABT-510, an anti-angiogenic thrombospondin-1 mimetic peptide exhibits favorable safety profile and early signals of activity in a randomized phase I trial. Proc Am Soc Clin Oncology. 2003, 22-

19.

Motzer R, Michaelson M, Redman B: Activity of SU 11248, a multitarged inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology. 2006, 24: 16-24. 10.1200/JCO.2005.02.2574.CrossRefPubMed

20.

Motzer R, Rini B, Bukowski R: Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006, 295: 2516-2524. 10.1001/jama.295.21.2516.CrossRefPubMed

21.

Motzer RJ, Hutson TE, Tomczak P: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N EnglJ Med. 2007, 356: 115-24. 10.1056/NEJMoa065044.CrossRef

22.

Figlin R, Hutson T, Tomczak M: Overall survival with sunitinib versus interfero -alfa as first line treatment of metastatic renal cell carcinoma. Journal of Clinical Oncology 2008 ASCO annual meeting Chicago, Illinois. 2008, 256s-

23.

O'Brien M, Russo P, Motzer R: Sunitinib therapy in renal cell carcinom. BJU International. 2008, 101: 1339-1342. 10.1111/j.1464-410X.2008.07506.x.CrossRefPubMed

24.

Rixe O, Bukowski RM, Michaelson MD: Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol. 2007, 8: 975-84. 10.1016/S1470-2045(07)70285-1.CrossRefPubMed

25.

Rini B, Wilding G, Hudes G, Stadler W: Axitinib in patients with metastatic renal cell cancer refractory to sorafenib. Journal of Clinical Oncology. 2007, 25-

26.

Dutcher J, Wilding G, Hudes G, Stadler W: Sequential axitinib therapy of patients with metastatic clear cell renal cell cancer refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib alone. Journal of Clinical Oncology Annual ASCO meeting 2008 Chicago, Illinois. 2008, 281s-

27.

Hutson T, Davis I, Machiels J, de Souza P: Pazopanib (GW786034) is active in metastatic renal cell carcinoma: interim results of a phase II randomized discontinuation trial. Journal of Clinical Oncology ASCO meeting 2007 Chicago, Illinois. 2007, abstract #5031-

28.

Hutson T, Davis D, Machiels J, de Souza P: Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor. Journal of Clinical Oncology 2008 annual ASCO meeting Chicago, Illinois. 2008, 261s-

29.

Sridhar S, Mackenzie M, Hotte S, Mukherjee C: Activity of cediranib (AZD2171) in patients with previously untreated metastatic renal cell cancer. A phase II trial of the PMH Consortium. Journal of Clinical Oncology Annual ASCO meeting 2008 Chicago, Illinois. 2008, 261s-

30.

Yu Y, Sato J: MAP kinases, phosphatidylinositol 3-kinase, and p70 S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothelial growth factor. J Cell Physiology. 1999, 178: 235-246. 10.1002/(SICI)1097-4652(199902)178:2<235::AID-JCP13>3.0.CO;2-S.CrossRef

31.

Schmelzle T, Hall M: TOR, a central controller of cell growth. Cell. 2000, 103: 253-262. 10.1016/S0092-8674(00)00117-3.CrossRefPubMed

32.

Atkins M, Hidalgo M, Stadler W: Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. Journal of Clinical Oncology. 2004, 22: 909-918. 10.1200/JCO.2004.08.185.CrossRefPubMed

33.

Hudes G, Carducci M, Tomczak P: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine. 2007, 356: 2271-10.1056/NEJMoa066838.CrossRefPubMed

34.

Jac J, Giessinger S, Khan M, Willis J: A phase II trial of RAD001 in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology. 2007, 25-

35.

Motzer R, Escudier B, Oudard S, Porta C: RAD001 versus placebo in patients with metastatic renal cell carcinoma after progressio on VEGFr-TKI therapy: Results from a randomized, double-blind multicenter phase III study. Journal of Clinical Oncology 2008 ASCO annual meeting Chicago, Illinois. 2008, 1009s-

36.

Rosenberg J, Weinberg V, Claros C, Ryan C: Phase I study of sorafenib and RAD001 for metastatic clear cell renal cell carcinoma. Journal of Clinical Oncology 2008 ASCO annual meeting Chicago, Illinois. 2008, 276s-

37.

Whorf R, Hainsworth D, Spiegel D: Phase II study of bevacizumab and everolimus in the treatment of advanced renal cell carcinoma. Journal of Clinical Oncology 2008 ASCO annual meeting Chicago, Illinois. 2008, 252s-

38.

Daliani DD, Papandreou CN, Thall PF: A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma. Cancer. 2002, 95: 758-65. 10.1002/cncr.10740.CrossRefPubMed

39.

Escudier B, Lassau N, Couanet D: Phase II trial of thalidomide in renal-cell carcinoma. Ann Oncol. 2002, 13: 1029-35. 10.1093/annonc/mdf213.CrossRefPubMed

40.

Motzer RJ, Berg W, Ginsberg M: Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol. 2002, 20: 302-6. 10.1200/JCO.20.1.302.CrossRefPubMed

41.

Srinivas S, Guardino AE: A lower dose of thalidomide is better than a high dose in metastatic renal cell carcinoma. BJU Int. 2005, 96: 536-9. 10.1111/j.1464-410X.2005.05680.x.CrossRefPubMed

42.

Lee CP, Patel PM, Selby PJ: Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006, 24: 898-903. 10.1200/JCO.2005.03.7309.CrossRefPubMed

43.

Amato RJ, Malya R, Rawat A: Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma. Am J Clin Oncol. 2008, 31: 237-43.CrossRefPubMed

44.

Amato R, Hernandez-McClain J, Saxena S, Khan M: Lenalidomide Therapy for Metastatic Renal Cell Carcinoma. American Journal of Clinical Oncology. 2008, 31: 244-249.PubMed

45.

Choueiri TK, Dreicer R, Rini BI: Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. Cancer. 2006, 107: 2609-16. 10.1002/cncr.22290.CrossRefPubMed

46.

Patel PH, Kondagunta GV, Schwartz L: Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma. Invest New Drugs. 2008, 26: 273-6. 10.1007/s10637-007-9107-y.CrossRefPubMed

47.

Presta L, Chen H, O'Connor S, Chisholm V: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Research. 1997, 57: 4593-99.PubMed

48.

Yang J, Haworth L, Sherry R, Hwu P: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. New England Journal of Medicine. 2003, 349: 427-34. 10.1056/NEJMoa021491.PubMedCentralCrossRefPubMed

49.

Escudier B, Pluzanska A, Koralewski P: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007, 370: 2103-11. 10.1016/S0140-6736(07)61904-7.CrossRefPubMed

50.

Jonasch E, Wood C, Matin S, Tamboli P: Presurgical bevacizumab in patients with metastatic clear cell renal cell carcinoma: A phase II study. Journal of Clinical Oncology Annual ASCO meeting 2008 Chicago Illinois. 2008, 275s-

51.

Garcia J, Rini B, Mekhail T, Triozzi P: A phase II trial of low dose interleukin-2 and bevacizumab in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology Annual ASCO meeting 2007 Chicago, Illinois. 2007, 18s-

52.

Cooney M, Garcia J, Dreicer R, Beatty K: A phase I study of bevacizumab in combination with sunitinib in advanced solid tumors. Journal of Clinical Oncology Annual ASCO meeting 2007 Chicago Illinois. 2007, 18s-

53.

Merchan J, Lieu G, Fitch T, Picus J: Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: phase I safety and activity results. Journal of Clinical Oncology Annual ASCO meeting 2007 Chicago Illinois. 2007, 18s-

54.

Bukowski RM, Kabbinavar FF, Figlin RA: Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol. 2007, 25: 4536-41. 10.1200/JCO.2007.11.5154.CrossRefPubMed

55.

Hainsworth JD, Sosman JA, Spigel DR: Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol. 2005, 23: 7889-96. 10.1200/JCO.2005.01.8234.CrossRefPubMed

56.

Uemura H, Nakagawa Y, Yoshida K, Saga S: MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Journal of Cancer. 1999, 81: 741-46. 10.1038/sj.bjc.6690757.CrossRef

57.

Bleumer I, Oosterwijk E, Oosterwijk-Wakka J: A Clinical Trial with Chimeric monoclonal Antibody WX-G250 and Low Dose Interleukin-2 Pulsing Scheme for Advanced Renal Cell Carcinoma. Journalof Urology. 2006, 175: 57-10.1016/S0022-5347(05)00040-6.CrossRef

58.

Huang M, Menefee M, Edgerly H, Kotz M: Ixabepilone (BMS-247550) and metastatic renal cell carcinoma. Journal of Clinical Oncology Annual ASCO meeting 2008 Chicago, Illinois. 2008, 262s-

59.

Mike S, Harrison C, Coles B: Chemotherapy for hormone refractory prostate cancer. Cochrane Database Syst Rev. 2006, 4-

60.

Tannock I, de Wit R, Berry W: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New England Journal of Medicine. 2004, 351: 1502-1512. 10.1056/NEJMoa040720.CrossRefPubMed

61.

Petrylak D, Tange C, Hussain M: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. New England Journal of Medicine. 2004, 351: 1513-20. 10.1056/NEJMoa041318.CrossRefPubMed

62.

Stenberg C, Whelan P, Hetherington J: Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology. 2005, 68: 2-9. 10.1159/000084201.CrossRef

63.

Sternberg C, Petrylak D, Witjes F: Satraplatin demonstrates significant clinical benefits for the treatment of patients with HRPC: results of a randomized phase III trial. Journal of Clinical Oncology. 2007, 25: 5019-10.1200/JCO.2007.11.8711.CrossRef

64.

Sartor A, Petrylak D, Witjes J, Berry W: Satraplatin in patients with advanced hormone-refratory prostate cancer: Overall survival results from teh phase III satraplatin and prednisone against refractory cancer (SPARC) trial. Journal of Clinical Oncology Annual ASCO meeting 2008 Chicago, Illinois. 2008, 250s-

65.

Bergers G, Benjamin L: Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003, 3: 401-410. 10.1038/nrc1093.CrossRefPubMed

66.

Reese D, Harris K, Corry M: A phase II trial of humanized anti-vascular endothelial growth factor antibody for the treatment of androgen-independent prostate cancer. Prostate Journal. 2001, 3: 65-70. 10.1046/j.1525-1411.2001.32007.x.CrossRef

67.

Picus J, Halabi S, Rini B: The use of bevacizumab with docetaxel and estramustine in hormone refractory prostate cancer: initial results of CALGB 90006. Proc Am Soc Clin Oncology. 2003, 22: 1578-

68.

Figg W, Dahut W, Duray P: A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res. 2001, 7: 1888-93.PubMed

69.

Dahut W, Gulley J, Arlen P: Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. Journal of Clinical Oncology. 2004, 22: 2532-39. 10.1200/JCO.2004.05.074.CrossRefPubMed

70.

Ning Y, Arlen P, Gulley J, Stein : Phase II trial of thalidomide, bevacizumab, and docetaxel in patients with metastatic castration-refractory prostate cancer. Journal of clinical Oncology annual ASCO meeting 2008 Chicago, Illinois. 2008, 250s-

71.

Chi KN, Ellard SL, Hotte SJ: A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann Oncol. 2008, 19: 746-51. 10.1093/annonc/mdm554.CrossRefPubMed

72.

Dahut WL, Scripture C, Posadas E: A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res. 2008, 14: 209-14. 10.1158/1078-0432.CCR-07-1355.CrossRefPubMed

73.

Smith MP, Kantoff M, Regan D, Kaufman MD: Michaelson: Phase II study of sunitinib malate in men with advanced prostate cancer, 2008 Genitourinary Cancers Symposium. 2008, Abstract No: 198-

74.

Periman POG, Sonpavde DM, Bernold DJ, Weckstein A, Williams F, Zhan KA, Boehm L, Asmar TE: Hutson: Sunitinib malate for metastatic castration resistant prostate cancer following docetaxel-based chemotherapy. J Clin Oncol. 2008, 26 (20 suppl): abstr 5157-

75.

Karakunnel JJJL, Gulley PM, Arlen M, Mulquin JJ, Wright IB, Turkbey P, Choyke CM, Ahlers WD, Figg WL: Dahut: Phase II trial of cediranib (AZD2171) in docetaxel-resistant, castrate-resistant prostate cancer (CRPC). J Clin Oncol. 2008, 26 (20 suppl): abstr 5136.

76.

Hussain M, Tangen C, Lara P: Ixabepilone (epothione B analogue BMS-247550) is active in chemotherapy naïve patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. Journal of Clinical Oncology. 2005, 23: 8724-29. 10.1200/JCO.2005.02.4448.CrossRefPubMed

77.

Lin A, Rosenberg J, Weinberg V: Clinical outcome of taxane-resistant hormone refractory prostate cancer in patients treated with subsequent chemoteherapy (ixabepilone or mitoxantrone/prednisone). Proc Am Soc Lin Oncol. 2006, 24: 231s-

78.

Harzstark A, Weinberg V, Sharib J, Smith D: Second line combination chemotherapy: A phase I study of ixabepilone, mitoxantrone and prednisone in patients with metastatic hormone-refractory prostate cancer refractory to docetaxel-based therapy. Journal of Clinical Oncology Annual ASCO meeting 2008 Chicago, Illinois. 2008, 287s-

79.

Wilding G, Chen Y, Dipaola P, Carducci M: E3803: Updated results on phase II study of weekly schedule of BMS-247550 for patients with castrate refractory prostate cancer. Journal of Clinical Oncology Annual ASCO meeting 2008 Chicago Illinois. 2008, 267s-

80.

Chi K, Beardsley E, Venner P, Eigl B: A phase II study of patupilone in patients with metastatic hormone refractory prostate cancer who have progressed after docetaxel. Journal of Clinical Oncology Annual ASCO meeting 2008 Chicago Illinois. 2008, 290s-

81.

Graff J, Smith D, Neerukonda L, Alonso M: Phase II study of sagopilone (ZK-EPO) plus prednisone as first-line chemotherapy in patients with metastatic androgen-independent prostate cancer. Journal of Clinical Oncology Annual ASCO meeting 2008 Chicago Illinois. 2008, 284s-

82.

Bradley D, Daignault S, Ryan C, Dipaola R: Cilengitide in asymptomatic metastatic androgen independent prostate cancer patients: a randomized phase II trial. Journal of Clinical Oncology Annual ASCO meeting 2008 Chicago Illinois. 2008, 285s-

83.

De Bono J, Attard G, Reid A, Parker C: Anti-tumor activity of abiraterone acetate, a CYP17 inhibitor of androgen synthesis, in chemotherapy naïve and docetaxel pre-treated castration resistant prostate cancer. Journal of Clinical Oncology Annual ASCO meeting 2008 Chicago Illinois. 2008, 251s-

84.

Danila D, Rathkopf D, Morris M, Slovin S: Abiraterone acetate and prednisone in patients with progressive metastatic castration resistant prostate cancer after failure of docetaxel-based chemotherapy. Journal of Clinical Oncology Annual ASCO meeting 2008 Chicago Illinois abstract #5019 254s: Abiraterone acetate and prednisone in patients with progressive metastatic castration resistant prostate cancer after failure of docetaxel-based chemotherapy. Journal of Clinical Oncology Annual ASCO meeting 2008 Chicago Illinois. 2008, 254s-

85.

Ryan C, Smith m, Rosenberg J, Lin a: Impact of prior ketoconazole therapy on response proportion to abiraterone acetate, a 17-alpha hydroxylase C17, 20-lyase inhibitor in castration resistant prostate cancer. Journal of Clinical Oncology Annual ASCO meeting 2008 Chicago Illinois. 2008, 254s-

86.

Maase Von der H, Sengelov L, ROberts J: Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. Journal of Clinical Oncology. 2005, 23: 4602-08. 10.1200/JCO.2005.07.757.CrossRefPubMed

87.

Sweeney C, Roth B, Kabbinavar F: Phase II study of pemetrexed for second line treatment of transitional cell carcinoma of teh urothelium. Journal of Clinical Oncology. 2006, 24: 3451-57. 10.1200/JCO.2005.03.6699.CrossRefPubMed

88.

Maase Von der H, Lehmann J, Gravis G: A phase II trial of pemetrexed plus gemcitabine as first-line treatment for locally advanced or metastatic transitional cell carcinomaof the urothelium. Proc Am Soc Clin Oncology. 2005, 23-

89.

Culine S, Theodore C, De Santis M: A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. British Journal of Cancer. 2006, 94: 1395-1401. 10.1038/sj.bjc.6603118.PubMedCentralCrossRefPubMed

90.

Molins J, Maase Von der H, Thodore C, Demkov T: Randomized phase III trial of vinflunine plus best supportive care vs best supportive care alone as 2nd line therapy after a platinum-containing regimen in advanced transitional cell carcinoma of the urothelium. Journal of Clinical Oncology Annual ASCO meeting 2008 Chicago, Illinois. 2008, 257s-

91.

Hussain M, MacVicar G, Petrylak D: Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2neu- positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. Journal of Clinical Oncology. 2007, 25: 2218-24. 10.1200/JCO.2006.08.0994.CrossRefPubMed

92.

Wulfing C, Machiels J, Richel D: A single arm, multicenter, open label, phase II study of lapatinib as 2L treatment of locally advanced/metastatic transitional cell carcinoma of tehr urothelial tract. Proc Am Soc Clin Oncology. 2005, 23-

93.

Gallagher D, Milowsky M, Gerst S, Iasonos A: Final results of a phase II study of sunitinb in patients with relapsed or refractory urothelial carcinoma. Journal of clinical Oncology annual ASCO meeting 2008 Chicago, Illinois. 2008, 270s-

94.

Dreicer R, Li H, Stein M, DiPaola R: Phase II trial of sorafenib in advanced carcinoma of the urothelium (E 1804): A trial of teh Eastern Cooperative Oncology Group. Journal of Clinical Oncology Annual ASCO meeting 2008 Chicago, Illinois. 2008, 270s-

95.

Oliver R, Mead G, Fogarty P: Radiotherapy versus carboplatin for stage I seminoma: Updated analysis of the MRC/EORTC randomised trial (ISRCTN27163214). Journal of Clinical Oncology Annual ASCO meeting 2008 Chicago Illinois. 2008, 1006s-

96.

Beyer J, Stenning S, Gerl A, Fossa S, Siegert W: High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched-pair analysis. Annals of Oncology. 2002, 13: 599-605. 10.1093/annonc/mdf112.CrossRefPubMed

97.

Pico J, Rosti G, Kramar A, Wandt HV: A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Annals of Oncology. 2005, 16: 1152-59. 10.1093/annonc/mdi228.CrossRefPubMed

98.

Lorch A, Kollmannsberger C, Hartmann J, Metzner B: Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumor: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. Journal of Clinical Oncology. 2007, 25: 2778-84. 10.1200/JCO.2006.09.2148.CrossRefPubMed

99.

Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995, 13 (3): 688-696.PubMed

100.

Fyfe GA, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC: Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1996, 14 (8): 2410-2411.PubMed

101.

Rini B RO: AG-013736, a multi-targeted tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase 2 study of cytokine-refractory, metastatic renal cell cancer. Journal of Clinical Oncology. 2005, 23 (abstract #4509):

Title: Novel therapies in genitourinary cancer: an update
Authors: David Chu
Shenhong Wu
Publication date: 01-12-2008
Publisher: BioMed Central
Published in: Journal of Hematology & Oncology / Issue 1/2008
Electronic ISSN: 1756-8722
DOI: https://doi.org/10.1186/1756-8722-1-11

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2008

Left sided inferior vena cava duplication and venous thromboembolism: case report and review of literature

Ganoderma lucidum polysaccharides can induce human monocytic leukemia cells into dendritic cells with immuno-stimulatory function

Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways

Rosai dorfman disease of the orbit

Journal of hematology & oncology: A journal open to all

Detection of NPM1 exon 12 mutations and FLT3 – internal tandem duplications by high resolution melting analysis in normal karyotype acute myeloid leukemia

Keynote webinar | Spotlight on antibody–drug conjugates in cancer